Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Acquired Stake in Sangamo Therapeutics, Inc

February 14, 2018 - By Louis Casey

 Julian Baker And Felix Baker's Baker Bros. Advisors Lp Acquired Stake in Sangamo Therapeutics, Inc

Investors sentiment decreased to 1.57 in Q3 2017. Its down 0.02, from 1.59 in 2017Q2. It is negative, as 17 investors sold Sangamo Therapeutics, Inc. shares while 32 reduced holdings. 27 funds opened positions while 50 raised stakes. 51.93 million shares or 2.16% more from 50.83 million shares in 2017Q2 were reported.

American Int Gru Inc holds 0% or 55,041 shares. Credit Suisse Ag has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). United Service Automobile Association reported 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Cormorant Asset Mgmt Lc reported 1.06% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Franklin Street Nc has invested 0.14% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Altrinsic Glob Ltd Liability Corp stated it has 0.31% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Moreover, Comerica Retail Bank has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Tower Research Limited Liability Corp (Trc) owns 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 2,551 shares. British Columbia – Canada-based Pacad has invested 0.04% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Baldwin Brothers Ma has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Amalgamated Financial Bank holds 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 10,550 shares. Meeder Asset Management stated it has 283 shares or 0% of all its holdings. Moreover, Swiss Bancshares has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Gilder Gagnon Howe And Company Limited Liability Company accumulated 30,923 shares. Baker Bros L P invested in 2.11M shares or 0.26% of the stock.

Since September 1, 2017, it had 0 insider buys, and 8 sales for $1.88 million activity. 5,000 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares with value of $85,545 were sold by Conner Edward R.. Mento Steven J had sold 11,520 shares worth $237,159 on Thursday, February 1. RINGO WILLIAM R sold $445,597 worth of stock.

The New Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Holding in Sangamo Therapeutics, Inc

Baker Bros. Advisors Lp reported SC 13G/A form with the SEC for Sangamo Therapeutics, Inc. Access it here: 000114420418007920. As reported by Julian Baker And Felix Baker’s Baker Bros. Advisors Lp, the filler owns 667% or 2,113,376 shares of the Health Care–company.

Sangamo Therapeutics, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s positive view for Sangamo Therapeutics, Inc. For a hedge fund managing $8.20 billion in assets and having 25+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s portfolio is in the sector.

Sangamo Therapeutics, Inc Institutional Sentiment

Filings show 134 investors own Sangamo Therapeutics, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 231106. 50149131 were owned by these investors. 18 funds opened new Sangamo Therapeutics, Inc stakes, 55 increased positions. There were 38 that closed positions and 33 reduced them.

Julian Baker And Felix Baker Baker Bros Advisors Lp is an investor bullish on Sangamo Therapeutics, Inc, owning 3755876 shares as of Q3 2015 for 0.20% of its portfolio. Alphagen Securities Llc owns 9650 shares or 0.41% of its portfolio. MA Mpm Asset Management Llc have 0.02% of its portfolio for 22487 shares. Further, Ra Capital Management Llc reported stake worth 1.17% of its portfolio. The NY Fic Capital Inc owns 881029 shares. Sangamo Therapeutics, Inc is 2.33% of its portfolio.

Business Profile

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

SEC Form 13G.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.18 earnings per share, down 28.57 % or $0.04 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

It closed at $20.55 lastly. It is up 29.78% since February 14, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.74 billion. The company's zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences has $25.0 highest and $4 lowest target. $18.20’s average target is -11.44% below currents $20.55 stock price. Sangamo Biosciences had 22 analyst reports since August 8, 2015 according to SRatingsIntel. The company was maintained on Wednesday, September 2 by Jefferies. Wedbush maintained the shares of SGMO in report on Monday, August 14 with “Hold” rating. PiperJaffray upgraded Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Wednesday, November 15 to “Overweight” rating. JP Morgan maintained it with “Overweight” rating and $22 target in Saturday, August 8 report. As per Tuesday, September 8, the company rating was downgraded by Zacks. The rating was downgraded by Janney Capital on Thursday, August 4 to “Neutral”. The company was downgraded on Wednesday, October 19 by PiperJaffray. Piper Jaffray maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) rating on Thursday, August 10. Piper Jaffray has “Hold” rating and $800 target. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Buy” rating by Jefferies on Friday, October 23. The firm earned “Buy” rating on Wednesday, September 2 by Wedbush.

More important recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Here’s Why Sangamo Therapeutics Rose as Much as 13.7% Today” on February 07, 2018, also Prnewswire.com published article titled: “Case Western Reserve and Sangamo Therapeutics Announce $11 Million NIH Grant …”, Prnewswire.com published: “Sangamo Presents Oncology Genome Editing Capabilities at Keystone Symposium on …” on February 13, 2018. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was released by: Prnewswire.com and their article: “Sangamo Therapeutics Announces Appointment Of Heather D. Turner As Senior Vice …” with publication date: February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.